Titre:
  • Abstract CT152: First in human study with EOS100850, a novel potent A2A antagonist, shows excellent tolerance and clinical benefit in immune resistant advanced cancers
Auteur:Buisseret, Laurence; Rottey, Sylvie; de Bono, Johann; Mossakowski, Manon; Delafontaine, Brant; Manickavasagar, Thubeena; Kotecki, Nuria; Martinoli, Carlo; Schneider, Manfred; De Henau, Olivier; Chevron, Patricia; Lagerfelt, Johan; Machiels, Jean Pascal
Informations sur la publication:Cancer research, 80, 16_Supplement, page (CT152-CT152)
Statut de publication:Publié, 2020-08-01
Sujet CREF:Médecine pathologie humaine
Langue:Anglais
Identificateurs:urn:issn:0008-5472
info:doi/10.1158/1538-7445.AM2020-CT152